The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE.
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene; MorphoSys
Research Funding - Celgene (Inst)
 
Betsy LaPlant
No Relationships to Disclose
 
William R Macon
No Relationships to Disclose
 
Morie A. Gertz
Honoraria - Celgene; Isis Pharmaceuticals; Med Learning Group; Millennium; Novartis; Onyx; Research to Practice; Sanofi
 
Thomas Matthew Habermann
No Relationships to Disclose
 
David James Inwards
No Relationships to Disclose
 
Ivana N. M. Micallef
No Relationships to Disclose
 
Donald B. Wender
No Relationships to Disclose
 
John Leonard
Consulting or Advisory Role - Celgene; Genentech/Roche; Teva
 
Thomas E. Witzig
Consulting or Advisory Role - Amgen
Research Funding - Celgene (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)